Ganlee Pharma Doses First Subject in Phase I Trial of GZC8072

Ganlee Pharmaceutical announced that its wholly-owned subsidiary, Ganlee Pharmaceutical Shandong Co. , Ltd. , has successfully completed first-subject dosing in a Phase I clinical trial of GZC8072 in China. GZC8072 is a next-generation, biased, ultra-long-acting oral weekly peptide formulation independently developed by Ganlee. The ongoing trial is evaluating the drug for indications including obesity, overweight, and type 2 diabetes.